[{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron||Iron (Fe)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"APOPHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Neurology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ APOPHARMA","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ APOPHARMA"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"European Commission | APOPHARMA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Neurology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ European Commission | APOPHARMA","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ European Commission | APOPHARMA"},{"orgOrder":0,"company":"Consorzio per Valutazioni Biologiche e Farmacologiche","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase III","graph3":"Consorzio per Valutazioni Biologiche e Farmacologiche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission"},{"orgOrder":0,"company":"Consorzio per Valutazioni Biologiche e Farmacologiche","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase III","graph3":"Consorzio per Valutazioni Biologiche e Farmacologiche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Consorzio per Valutazioni Biologiche e Farmacologiche \/ European Commission"},{"orgOrder":0,"company":"SocraTec R&D GmbH","sponsor":"SocraMetrics GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Undisclosed","graph2":"Phase I","graph3":"SocraTec R&D GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SocraTec R&D GmbH \/ SocraMetrics GmbH","highestDevelopmentStatusID":"6","companyTruncated":"SocraTec R&D GmbH \/ SocraMetrics GmbH"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Global Rare Diseases \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Undisclosed","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"APOPHARMA \/ Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"APOPHARMA \/ Food and Drug Administration"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase IV","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase IV","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Nephrology","graph2":"Phase III","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hematology","graph2":"Phase IV","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"CorMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Nephrology","graph2":"Phase III","graph3":"CorMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CorMedix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CorMedix \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Neurology","graph2":"Phase II","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Undisclosed","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Algorithme Pharma Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Undisclosed","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"APOPHARMA \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Undisclosed","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Nephrology","graph2":"Phase IV","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Inc \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Chiesi Group"},{"orgOrder":0,"company":"Neuroscience Trials Australia","sponsor":"The Florey Institute of Neuroscience and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Neurology","graph2":"Phase II","graph3":"Neuroscience Trials Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Neuroscience Trials Australia \/ The Florey Institute of Neuroscience and Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"Neuroscience Trials Australia \/ The Florey Institute of Neuroscience and Mental Health"}]
Find Clinical Drug Pipeline Developments & Deals for CP20
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
